Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KM 819

Next Previous
X
Search
Drug Profile

KM 819

Alternative Names: KM-819; KR-33493

Latest Information Update: 04 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chungnam National University; Korea Research Institute of Chemical Technology
  • Developer Chungnam National University; Kainos Medicines; Korea Research Institute of Chemical Technology; Parexel International
  • Class Antiparkinsonians
  • Mechanism of Action Apoptosis inhibitors; FAF1 protein expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 19 Aug 2024 Kainos Medicine terminates a phase II trial in Multiple system atrophy (In the elderly, Treatment-experienced, In adults) in South Korea (PO) as sponsor has decided to withdraw the study due to safety issue and re-initiate with a new clinical study (NCT05695378)
  • 27 Feb 2023 Phase-II clinical trials in Multiple system atrophy (In the elderly, Treatment-experienced, In adults) in South Korea (PO)(NCT05695378)
  • 25 Jan 2023 Kainos Medicine and Parexel plans a phase II trial for Multiple system atrophy in February 2023 (PO) (NCT05695378)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top